Analysis of Bevacizumab-Induced Gastrointestinal Perforation Using the Japanese Adverse Drug Event Report Database

Area of Science:

• Oncology
• Pharmacovigilance
• Clinical Trial Analysis

Background:

• Bevacizumab, a VEGF inhibitor, is used to treat various cancers.
• Bevacizumab-induced gastrointestinal perforation (BIGP) is a rare but serious adverse event.
• Understanding BIGP onset and outcomes is crucial for patient safety.

Purpose of the Study:

• To evaluate the time to onset of bevacizumab-induced gastrointestinal perforation (BIGP) across different cancer indications.
• To analyze the outcomes of BIGP.
• To assess the risk of BIGP when bevacizumab is combined with other anticancer agents.

Main Methods:

• Utilized the Japanese Adverse Drug Reaction Reports (JADER) database.
• Extracted gastrointestinal perforation (SMQ 20000107) reports.
• Performed time-to-onset analysis, outcome assessment, and association rule mining for combination therapies.

Main Results:

• Analyzed 2,112 BIGP reports from 887,704 adverse event reports.
• BIGP onset was significantly earlier in non-small cell lung cancer (46.0 days) compared to colorectal (77.0 days) and ovarian cancers (67.0 days).
• Association rule mining identified specific drug combinations associated with early (1-100 days) and later (101-200 days) BIGP onset.

Conclusions:

• Time to BIGP onset is significantly shorter in non-small cell lung cancer patients.
• This finding aids in the early detection and intervention of BIGP.
• Further research into combination therapies can refine risk assessment for BIGP.